Beyond the Market View: Unlocking Granular Patient and Provider Intelligence

A National Living Lab of EHR-Sourced Data, providing your internal analytics team with unparalleled visibility and actionable intelligence across the entire GLP-1 product lifecycle.

Competitive Intelligence

Regulatory Acceleration

Market Access Optimization

Clinical Development Precision

OBSURV AI: A Deeper Understanding of Patient and Provider Behavior that Only AI-Ready Clinical Notes Can Uncover

What if you could understand the why behind every GLP-1 decision?

OBSURV RWE AI-ready clinical notes empower your data scientists to deploy verified Large Language Models (LLMs) prompts, unlocking unique insights from clinical notes that claims and structured EHR data can’t touch.

Decision Driver Analysis

Understand exactly why doctors start, continue, switch, or stop GLP-1 therapies by patient type.

Symptom & Trajectory Mapping

Enrich your understanding of disease progression with clinician observations captured in notes.

Patient Reported Outcomes Monitoring

Gain deeper insights into patient challenges along their weight loss journeys.

Market-by-Market Insights

Pinpoint regional variations in GLP-1 prescribing preferences for hyper-targeted commercial strategies.

LLM – Ready Clinical Notes
de-identified, longitudinal, and unmatched depth:

LLM – Ready Clinical Notes
de-identified, longitudinal, and unmatched depth:

OBSURV AI: A Deeper Understanding of Patient and Provider Behavior that Only AI-Ready Clinical Notes Can Uncover

What if you could understand the why behind every GLP-1 decision?

OBSURV RWE AI-ready clinical notes empower your data scientists to deploy verified Large Language Models (LLMs), unlocking unique insights from clinical notes that claims and structured EHR data can’t touch.

  • Decision Driver Analysis: Understand exactly why doctors start, continue, switch, or stop GLP-1 therapies by specialty and patient type
  • Symptom & Trajectory Mapping: Enrich your understanding of disease progression with clinician observations captured in notes.
  • Patient Reported Outcomes Monitoring: Gain deeper insights into patient challenges along their weight loss journeys.  
  • Market-by-Market Insights: Pinpoint regional variations in GLP-1 prescribing preferences for hyper-targeted commercial strategies.
Overweight Patients
[BMI 27 – 29.9]
0 M
Obese Patients Class 1
[BMI 30 – 34.9]
0 M
Obese Patients Class 2
[BMI 35 – 39.9]
0 M
Obese Patients Class 3
[BMI > 40]
0 M

A New Standard in RWE Quality ... Delivered to Your GLP-1 Evidence Platform

Gain unparalleled market intelligence and a deeper understanding of patient and provider behavior across the US obesity market.